157 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
34
Ending by 2030
Jan 2027
Next term end
91
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2041 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends Feb 2040 · High confidence
NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS
US 11,759,516
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Variable Domains of Camelid Heavy-Chain Antibodies Directed Against Glial Fibrillary Acidic Proteins
US 8,460,888
The most cited patent in this portfolio, cited by 27 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2029.
Human Innate Lymphoid Cell Precursors: Identification, Characterization, Applications
US 11,680,245
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
Formerly held, still cited
Notable
Ends Feb 2036 · High confidence
Cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
now held by Sorbonne Universite
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Dec 11 to 20, 2026 · next Dec 11
- 1 fee due Jan 16, 2027The maintenance fee for Multiplex Immuno Screening Assay (US 10,352,930) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 7 fees due Feb 13 to 22, 2027 · next Feb 13
- 1 fee due Mar 19, 2027The maintenance fee for NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS (US 11,759,516) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 5 fees due Apr 8 to 20, 2027 · next Apr 8
- 1 fee due May 14, 2027The maintenance fee for Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics (US 11,815,513) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 5 fees due Jul 2 to 30, 2027 · next Jul 2
- 3 fees due Aug 2 to 27, 2027 · next Aug 2
- 7 fees due Sep 1 to 30, 2027 · next Sep 1
- 4 fees due Oct 2 to 30, 2027 · next Oct 2
- 3 fees due Nov 3 to 5, 2027 · next Nov 3
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
- 6 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 91 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,222,029 | A Lentiviral Vector-Based Vaccine held by Institut Pasteur, Centre National de la Recherche Scientifique and Institut National de la Sante et de la Recherche Medicale In force · High confidence | In force | High confidence | |
| US 7,736,850 | Novel Strain of SARS-Associated Coronavirus and Applications Thereof In force · High confidence | In force | High confidence | |
| US 10,767,167 | Polynucleotides Encoding MHC Class I-Restricted Htert Epitopes, Analogues Thereof or Polyepitopes In force · High confidence | In force | High confidence | |
| US 9,442,114 | Novel Isolated and Purified Strains of Chikungunya Virus and Polynucleotides and Polypeptides Sequences, Diagnostic and Immunogenical Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,888,041 | In Vitro Diagnostic Method and Kit for an Aspergillus Infection In force · High confidence | In force | High confidence | |
| US 9,005,961 | Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions In force · Medium confidence | In force | Medium confidence | |
| US 8,124,380 | Glycoconjugates and Their Use as Potential Vaccines Against Infection by Shigella Flexneri held by Inserm (Institut National de la Sante et de la Recherche Medicale), Institut Pasteur and Centre National de la Recherche Scientifique In force · High confidence | In force | High confidence | |
| US 9,422,548 | Ob-Fold Used as Scaffold for Engineering New Specific Binders In force · Medium confidence | In force | Medium confidence | |
| US 11,434,585 | Ob-Fold Used as Scaffold for Engineering New Specific Binders In force · Medium confidence | In force | Medium confidence | |
| US 9,499,799 | Cells and Methodology to Generate Non-Segmented Negative-Strand RNA Viruses In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 157: 38 patents in force now held by others · 195 patents ended · 81 applications pending · 241 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.